The investment is part of the company’s plan to expand their specialist facilities with a new 15,000 sq ft development which will manufacture tablets and capsules which meet the highest international Quality Standards. Speaking of the announcement, Dr Richard Yarwood, Chief Executive of Penn Pharma stated, “We are delighted to announce this significant investment in the UK pharmaceutical manufacturing sector at a time when the established industry remodels itself and out-sourcing is on the increase.”
Penn Pharma, based in the Welsh market town of Tredegar has also received funding and training support from the Welsh Assembly Government.
Penn, who currently employ 280 highly skilled staff, believe that people are at the heart of their success and are keen to keep highly skilled jobs within Wales. Yarwood stated, “Over recent years we have witness strong growth in our development and manufacturing services, we are expecting this to continue at an increasing rate post completion of the new facility. We wouldn’t have achieved such great year on year success if it wasn’t for the hard work of our skilled personnel.”
Penn Pharma is one of the longest established pharmaceutical services companies and has over 30 years experience in providing drug development, clinical trial supply and manufacturing services to the international healthcare industry.